肾衰宁片联合缬沙坦治疗慢性肾衰竭临床疗效  

Clinical Curative Effect of the Renal Failure Combined Valsartan Treatment on Patient with Chronic Renal Failure

作　　者：王小华[1] 陈建平[1] 金哲[1] 陈蓉[1] 廖爱能[1] 

机构地区：[1]三明市第二医院肾内科,福建省永安市366000

出　　处：《医学理论与实践》2015年第23期3183-3185,共3页The Journal of Medical Theory and Practice

摘　　要：目的:观察肾衰宁联合缬沙坦治疗慢性肾功能衰竭的临床疗效。方法:回顾性分析2012年3月-2015年6月在我院肾内科治疗的慢性肾功能衰竭患者210例,按治疗方法分为A组、B组和C组,三组患者均给予常规西医治疗,在常规治疗基础上A组予肾衰宁进行治疗,B组予缬沙坦治疗,C组则同时加用肾衰宁及缬沙坦,疗程3个月。治疗结束后,比较三组患者的临床疗效。结果:与治疗前比较,治疗后三组患者血肌酐、尿素氮均有明显下降,且C组下降更明显,差异有统计学意义(P<0.01)。C组患者治疗的总有效率明显高于A、B组,差异有统计学意义(P<0.01)。三组不良反应的发生率无显著性差异(P>0.05)。结论:肾衰宁片联合缬沙坦能显著降低CKD患者尿素氮与肌酐水平,延缓CKD进展,且安全性高,值得临床推广应用。Objective： To investigate the clinical curative effect observation of the renal failure combined valsartan treatment on patient with chronic renal failure. Methods： 210 patients with chronic renal failure were randomly divided into Shenshuaining group, valsartan group and the Shenshuaining combined valsartan group. We observe there months. Results：The serum creatinine and blood urea nitrogen were decreased in Shenshuaining group, valsartan group and the Shenshuaining combined valsartan group. The serum creatinine and blood urea nitrogen in the Shenshuaining combined valsartan group were lower than Shenshuaining group and valsartan group, there were significantly difference （P~ 0.01）. The total effective rate of Shenshuaining combined valsartan group was higher than the Shenshuaining group and valsartan group, there were significantly difference （P〈~0. 01）. The adverse reaction rate of Shenshuaining group,val- sartan group and the Shenshuaining combined valsartan group were not significantly difference （P〉0. 05）. Conclusion： The Shenshuaining combined valsartan can significantly improve renal function, delay renal function progress, and the safety is high, it is worthy of clinical application.

关 键 词：慢性肾功能衰竭 肾衰宁 缬沙坦 疗效观察 

分 类 号：R692[医药卫生—泌尿科学]